*UPDATED August 2019* Purchase of non-funded meningococcal vaccines
*UPDATED September 2019* Bexsero: A vaccine to protect against meningococcal group B disease
*UPDATED* Meningococcal disease
Quick answers to frequent meningococcal vaccine questions
Which vaccines protect against meningococcal disease?
No one vaccine covers all the meningococcal groups causing disease in New Zealand.
- Bexsero® protects against meningococcal group B, which is the cause of around 50% of cases/year.
- NeisVac-C® protects against meningococcal group C, which is the cause of around 10% of cases/year.
- Menactra® and Nimenrix® protect against meningococcal groups A, C, Y and W, which are the cause of around 50% of cases/year.
⇒ These vaccines are available for purchase by people with an increased risk of exposure to meningococcal bacteria or risk of invasive disease. Menactra is recommended and funded for children from 2 years of age and adults with a condition listed on the Pharmaceutical Schedule.
Should we recommend an A, C, Y and W vaccine over a B vaccine, or vice versa?
Health professionals are not advised to recommend an A, C, Y, W vaccine over a B vaccine or vice versa, a B vaccine over an A, C, Y, W vaccine. Health professionals cannot accurately predict who will get meningococcal disease or which meningococcal group could be the cause.
Can we give less doses of Bexsero if a person has a history of MeNZB vaccination?
No. Two doses of Bexsero are recommended for older children, adolescents and adults regardless of a history of MeNZB vaccination.
Can Bexsero be given at the same visit as Menactra or Nimenrix?
Yes. Menactra or Nimenrix and Bexsero can be administered at the same visit using different sites.
Is a minimum interval required between administration of Bexsero and Menactra or Nimenrix?
No. When Menactra or Nimenrix and Bexsero are not coadministered, no minimum interval is required before administration of the subsequent vaccine.
Is a minimum interval required between administration of Bexsero, Menactra or Nimenrix and any other vaccine?
Menactra** or Nimenrix and Bexsero can be administered at the same visit as any other vaccine or any interval before/after any other vaccine.
**except when Menactra and Prevenar® 13 are being administered, a minimum interval of 4 weeks is required between administration of these two vaccines.
Can a combination of Menactra and Nimenrix be used to deliver a primary course of meningococcal A, C, Y and W vaccines in children aged under 24 months?
Yes. Menactra is approved for use as a two dose vaccine course in children aged 9–23 months (inclusively). A child in this age group who receives one dose of Menactra can recieve either Menactra or Nimenrix a minimum of three months later to complete their primary vaccine course.
Can a pregnant woman receive Bexsero, Menactra or Nimenrix?
Yes. There are no safety concerns around administration of Menactra, Nimenrix or Bexsero at any stage of pregnancy. These are non-live vaccines and the advice is consistent with the recommendation for a pregnant woman to receive non-live vaccines when she has an increased risk of disease, for example influenza vaccination is recommended at any stage of pregnancy because they have an increased risk of influenza disease and complications.
Is a minimum interval required between administration of NeisVac-C and Menactra or Nimenrix?
No minimum interval is required between administration of NeisVac-C (meningococcal C only vaccine) and administration of a subsequent Menactra or Nimenrix. However, when Menactra is administered in place of the second NeisVac-C dose in children aged under 12 months a minimum interval of 8 weeks between the first NeisVac-C and administration of Menactra could be considered. In this situation, a second Menactra administered 3 months later would still be recommended to complete the primary vaccine doses for the meningococcal A, Y and W antigens.
Which meningococcal vaccine fact sheet should I print first?
Northland community meningococcal W vaccination programme (ended 30 April 2019)
Ministry of Health Meningococcal vaccines: Eligibility, recommendations and supply